2-(4-氰基苯氧基)乙酸甲酯 | 272792-14-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-氰基苯氧基)乙酸甲酯
• 中文别名: (4-氰基苯氧基)乙酸甲酯
• 英文名称: methyl 2-(4-cyanophenoxy)acetate
• 英文别名: Methyl (4-cyanophenoxy)acetate
• CAS: 272792-14-0
• 化学式: C₁₀H₉NO₃
• mdl: MFCD05855148
• 分子量: 191.186
• InChiKey: MAVSETCJUQQWBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  59.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2926909090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl (4-cyanophenoxy)acetate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl (4-cyanophenoxy)acetate
CAS number: 272792-14-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H9NO3
Molecular weight: 191.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(4-氰基苯氧基)乙酸甲酯 在 ammonium hydroxide 、 氢气 、 镍 作用下， 以 甲醇 为溶剂， 生成 乙酸,[4-(氨基甲基)苯氧基]-,甲基酯
  参考文献：
  名称：

  发现含羧基的联芳基脲作为有效的RORγt反向激动剂。

  摘要：

  GSK805（1）是一种强效RORγt反向激动剂，但缺点1是它的低溶解度，从而导致在高剂量有限的吸收。我们已经探索了1的酰胺连接基，联芳基和芳基磺酰基部分的详细结构-活性关系，试图在保持RORγt活性的同时提高溶解度。结果，发现了一系列新颖的含羧基联芳基脲衍生物，作为具有改进的类药物性质的有效RORγt反向激动剂。化合物3i显示了强大的RORγt抑制活性和亚型选择性，在RORγFRET分析中的IC 50为63.8 nM，在基于细胞的RORγ-GAL4启动子报告子分析中为85 nM。合理的3i抑制活性在小鼠Th17细胞分化试验中也获得了抑制（在0.3μM时抑制76％）。此外，与1相比，3i在pH 7.4时具有大大改善的水溶解度，表现出体面的小鼠PK曲线，并在咪喹莫特诱导的牛皮癣小鼠模型中表现出一定的体内功效。

  DOI：

  10.1016/j.ejmech.2020.112536
• 作为产物：
  描述：

  对溴苯氧乙酸 在 四(三苯基膦)钯 、 氯化亚砜 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 2-(4-氰基苯氧基)乙酸甲酯
  参考文献：
  名称：

  发现含羧基的联芳基脲作为有效的RORγt反向激动剂。

  摘要：

  GSK805（1）是一种强效RORγt反向激动剂，但缺点1是它的低溶解度，从而导致在高剂量有限的吸收。我们已经探索了1的酰胺连接基，联芳基和芳基磺酰基部分的详细结构-活性关系，试图在保持RORγt活性的同时提高溶解度。结果，发现了一系列新颖的含羧基联芳基脲衍生物，作为具有改进的类药物性质的有效RORγt反向激动剂。化合物3i显示了强大的RORγt抑制活性和亚型选择性，在RORγFRET分析中的IC 50为63.8 nM，在基于细胞的RORγ-GAL4启动子报告子分析中为85 nM。合理的3i抑制活性在小鼠Th17细胞分化试验中也获得了抑制（在0.3μM时抑制76％）。此外，与1相比，3i在pH 7.4时具有大大改善的水溶解度，表现出体面的小鼠PK曲线，并在咪喹莫特诱导的牛皮癣小鼠模型中表现出一定的体内功效。

  DOI：

  10.1016/j.ejmech.2020.112536

文献信息

• 6-Aminoisoquinoline Compounds
  申请人：deLong Mitchell A.

  公开号：US20080167340A1

  公开（公告）日：2008-07-10

  6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.

  提供了影响、抑制或减少激酶作用的6-氨基异喹啉化合物。还提供了包括治疗有效量的6-氨基异喹啉化合物和药用可接受载体的药物组合物。还提供了使用这些化合物和/或组合物来影响疾病状态或疾病条件，如癌症、肥胖和青光眼的各种方法。
• Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
  申请人：Bombrun Agnes

  公开号：US20050043388A1

  公开（公告）日：2005-02-24

  The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of oxindole hydrazide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs, in particular of PTP1B, TC-PTP, SHP and GLEPP-1. The present invention is furthermore related to novel oxindole hydrazide derivatives and method of preparation thereof.(I).

  本发明涉及使用式(I)的氧化吲哚肼衍生物治疗和/或预防由胰岛素抵抗或高血糖介导的代谢紊乱，包括1型和/或2型糖尿病、不适当的葡萄糖耐受性、胰岛素抵抗、高脂血症、高三酰甘油血症、高胆固醇血症、肥胖症、多囊卵巢综合症（PCOS）。特别地，本发明涉及使用式(I)的氧化吲哚肼衍生物来调节，特别是抑制PTPs的活性，特别是PTP1B、TC-PTP、SHP和GLEPP-1。本发明还涉及新的氧化吲哚肼衍生物及其制备方法。
• 6-AMINOISOQUINOLINE COMPOUNDS
  申请人：deLong Mitchell A.

  公开号：US20110183965A1

  公开（公告）日：2011-07-28

  6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.

  本发明提供了影响、抑制或减少激酶作用的6-氨基异喹啉化合物。还提供了包括治疗有效量的6-氨基异喹啉化合物和药学上可接受的载体的制药组合物。还提供了使用这些化合物和/或组合物影响疾病状态或病症，如癌症、肥胖和青光眼的各种方法。
• OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS)
  申请人：BOMBRUN Agnes

  公开号：US20100168101A1

  公开（公告）日：2010-07-01

  The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of oxindole hydrazide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs, in particular of PTP1B, TC-PTP, SHP and GLEPP-1. The present invention is furthermore related to novel oxindole hydrazide derivatives and method of preparation thereof.

  本发明涉及使用式(I)的氧化吲哚肼衍生物治疗和/或预防由胰岛素抵抗或高血糖介导的代谢障碍，包括1型和/或2型糖尿病、不足的葡萄糖耐受性、胰岛素抵抗、高脂血症、高三酰甘油血症、高胆固醇血症、肥胖和多囊卵巢综合症（PCOS）。特别地，本发明涉及使用式(I)的氧化吲哚肼衍生物调节，特别是抑制PTP的活性，尤其是PTP1B、TC-PTP、SHP和GLEPP-1的活性。本发明还涉及新的氧化吲哚肼衍生物及其制备方法。
• 6-aminoisoquinoline compounds
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US08034943B2

  公开（公告）日：2011-10-11

  6-Aminoisoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.

  本发明提供了影响、抑制或减少激酶作用的6-氨基异喹啉化合物。还提供了包括治疗有效量的6-氨基异喹啉化合物和药用可接受载体的制药组合物。还提供了使用该化合物和/或组合物来影响疾病状态或条件，如癌症、肥胖症和青光眼的各种方法。